Impaired microtubule function correctable by cyclic GMP and cholinergic agonists in the Chediak-Higashi syndrome.
The Chediak-Higashi (CH) syndrome of man and several animal species is characterized by the presence of abnormal giant granules in all granule-containing cells and by defects in chemotaxis and lysosomal degranulation during phagocytosis in polymorphonuclear leukocytes (PMNs). Since similar functional abnormalities have been reported in normal PMNs following exposure to colchicine and other agents that disrupt microtubles it was proposed that microtubule function may be impaired in the CH syndrome. The mobility of concanavalin A (con A)-receptor complexes on PMN membranes was used to test microtubule integrity. Normal PMNs showed a uniform distribution of membrane-bound con A. By contrast, con A was aggregated into surface caps on both colchicine-treated normal PMNs and untreated PMNs from mice and a patient with CH syndrome. This result is consistent with impaired microtubule function in the CH cells. The spontaneous capping response of CH PMNs was inhibited by cyclic GMP and by cholinergic agonists that can elevate cyclic GMP levels in neutrophils. This raised the possibility that the microtubule defect in CH cells may be correctable by treatments that increase cyclic GMP generation. Direct evidence for both the absence of microtubule assembly in con A-treated PMNs from the CH patient and for normal microtubule assembly in CH PMNs incubated with cyclic GMP and cholinergic agonists prior to con A treatment was obtained by electron microscopy. In addition, evidence for a direct relationship between the microtubule defect and the development of giant lysosomes in CH cells was obtained. Thus, CH fibroblasts grown in vitro developed abnormal lysosomes in the majority of cells. However, the same cells cultured in the presence of cholinergic agonists developed a majority of lysosomes that were morphologically normal at the level of the light microscope. Similarly, granule morphology appeared normal in peripheral blood leukocytes from mice treated chronically in vivo with cholinergic agonists.
D000818:Animals; D002609:Chediak-Higashi Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D002633:Chemotaxis; D003078:Colchicine / Q000627:therapeutic use; D003208:Concanavalin A / Q000378:metabolism; D000242:Cyclic AMP / Q000494:pharmacology / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000494:pharmacology / Q000627:therapeutic use; D003594:Cytoplasmic Granules / Q000187:drug effects / Q000648:ultrastructure; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D051379:Mice; D008870:Microtubules / Q000502:physiology*; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use*; D010587:Phagocytosis; D011955:Receptors, Drug
D006023:Glycoproteins; D010276:Parasympatholytics; D011955:Receptors, Drug; D003208:Concanavalin A; D000242:Cyclic AMP; D006152:Cyclic GMP; D003078:Colchicine